| 2.43 -0.42 (-14.74%) | 11-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.6 |
1-year : | 4.19 |
| Resists | First : | 3.08 |
Second : | 3.58 |
| Pivot price | 2.84 |
|||
| Supports | First : | 2.26 |
Second : | 1.88 |
| MAs | MA(5) : | 2.69 |
MA(20) : | 2.89 |
| MA(100) : | 2.69 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.5 |
D(3) : | 26.9 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 3.58 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ STXS ] has closed below the lower bollinger band by 10.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 49.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.56 - 2.57 | 2.57 - 2.58 |
| Low: | 2.24 - 2.25 | 2.25 - 2.26 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Wed, 12 Nov 2025
Stereotaxis, Inc. SEC 10-Q Report - TradingView
Wed, 12 Nov 2025
Stereotaxis shares drop after Q3 loss widens, GenesisX limited launch underway (STXS:NYSE) - Seeking Alpha
Wed, 12 Nov 2025
Stereotaxis Inc (STXS) Q3 2025 Earnings Call Highlights: Navigating Growth Amidst Financial ... - Yahoo Finance
Tue, 11 Nov 2025
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates - sharewise.com
Tue, 11 Nov 2025
Stereotaxis (STXS) Reports Q3 Revenue Below Expectations - GuruFocus
Mon, 10 Nov 2025
Stereotaxis (NYSE: STXS) receives U.S. FDA 510(k) for GenesisX, 80% smaller cabinet - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 85 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 48.9 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 3,200 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | -87.4 % |
| Operating Margin | -133.8 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -94.9 % |
| Qtrly Rev. Growth | -42.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -9.39 |
| PEG Ratio | 0 |
| Price to Book value | 17.42 |
| Price to Sales | 8.69 |
| Price to Cash Flow | -23.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|